Java turmeric Curcuma zanthorrhiza Roxb.
Also called: Javanese turmeric, temulawak (temoe lawak), Curcuma xanthorrhiza (spelling used by EMA and the European Pharmacopoeia)
Java turmeric is a Curcuma species distinct from common turmeric (Curcuma longa). Its dried, sliced rhizome is an EU traditional herbal medicine for digestive complaints, taken as herbal tea or as ethanol or acetone dry extracts.
- Category
- Botanical
- Part used
- Rhizome (dried, sliced)
- Strongest evidence
- C Limited
- Native range
- Native to southwestern India (POWO: "SW. India"); introduced in Indonesia (Java), much of Southeast Asia and elsewhere
- Reviewed
- 2026-10-29
Class 3 Limited studies in people. One RCT of Curcuma xanthorrhiza alone was found: a 3-month double-blind trial in adults with lupus (20 mg three times daily versus placebo, both groups also given vitamin D3) found no effect on disease activity. No other human trial was found in PubMed. [7]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CStomach and gut1 topic
CImmune system and infection1 topic
DMouth and teeth1 topic
DCancer1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Digestive complaints (fullness, slow digestion, flatulence) | C | EMA found insufficient clinical-trial evidence; EU use rests on long-standing traditional use. A 12-person study of curcumin (20-80 mg) showed gallbladder contraction, which EMA judged insufficient for firm conclusions. [2] |
| Antibacterial activity of xanthorrhizol against caries bacteria | D | A 2021 systematic review of 11 studies (all in vitro except one trial that disinfected children's toothbrushes) found xanthorrhizol inhibited caries-causing bacteria such as Streptococcus mutans; clinical studies are still needed. [3] |
| Anti-inflammatory and anticancer effects | D | EMA's 2014 assessment describes xanthorrhizol's effects only from in vitro and animal studies; the few human data it cites concern curcumin, and it cited no clinical data for Java turmeric itself. [1] |
| Disease activity in lupus (added to vitamin D3) | C | A 3-month double-blind RCT in adults with active lupus and low vitamin D found Curcuma xanthorrhiza (20 mg three times daily) added to vitamin D3 had no effect on disease activity, IL-6 or TGF-β1 versus placebo. [7] |
Main constituents: Curcuminoids (1-2%): curcumin and monodemethoxycurcumin, plus other diarylheptanoids [1]; Volatile oil (3-12%), mainly sesquiterpenes (e.g., beta-curcumene, ar-curcumene) and xanthorrhizol (44.5% of the oil), with a little camphor [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Stated in the EU herbal monograph (traditional use, adults; HMPC, adopted 28 January 2014): herbal tea, 1 g comminuted rhizome in 100 ml boiling water 3 times daily; dry extract (DER 20-50:1, ethanol 96%) 8-13 mg 3 times daily; dry extract (DER 9-12:1, acetone) 50-100 mg twice daily. [4]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
No LiverTox chapter found. EMA does not recommend use with liver disease, gallstones or bile-duct obstruction because of possible stimulation of bile secretion.
Details and sources - Pregnancy and breastfeedingEU monograph: safety during pregnancy and lactation has not been established; use is not recommended. No fertility data.
1 statement in the profile.
Details and sources - Interactions with medicines1 listed
Drugs in general
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Stated in the EU herbal monograph (traditional use, adults; HMPC, adopted 28 January 2014): herbal tea, 1 g comminuted rhizome in 100 ml boiling …
Details and sources
- Because it may stimulate bile secretion, EMA does not recommend it with bile-duct obstruction, cholangitis, liver disease, gallstones or other biliary diseases. [4]
- Mild gastrointestinal effects such as dry mouth, flatulence and gastric irritation may occur; frequency unknown. [4]
- Not recommended during pregnancy and lactation (safety not established) or under 18 years (no adequate data). Reproductive toxicity, genotoxicity and carcinogenicity tests have not been performed. [4]
Interactions
| With | What happens |
|---|---|
| Drugs in general | EMA's monograph lists no reported interactions; curcumin inhibits several CYP enzymes in vitro, but EMA judged interactions unlikely at monograph doses. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- European Pharmacopoeia monograph 1441 requires at least 50 ml/kg essential oil and at least 1.0% dicinnamoyl methane derivatives (as curcumin) in the anhydrous drug. [1]
- The presence of xanthorrhizol and absence of bisdemethoxycurcumin distinguish Javanese turmeric from common turmeric (Curcuma longa). [1]
Regulatory status
- EU: EU herbal monograph based on traditional use; applications for herbal medicines are assessed by national authorities. [2]
- US: FDA states that, by law, it does not approve dietary supplements or their labeling; under DSHEA it has no authority to approve them before they are marketed, and firms are responsible for their products' safety and labeling. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming Java turmeric (Curcuma zanthorrhiza / C. xanthorrhiza, temulawak) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No LiverTox chapter found. EMA does not recommend use with liver disease, gallstones or bile-duct obstruction because of possible stimulation of bile secretion. [P4]
Interactions with medicines
- Drugs in general: EMA's monograph lists no reported interactions; curcumin inhibits several CYP enzymes in vitro, but EMA judged interactions unlikely at monograph doses. [P1]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component before use — 21 CFR 111.75(a)(1)(i) requires at least one appropriate identity test or examination unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P5]
- Ph. Eur. 1441 assays: essential oil (min. 50 ml/kg) and dicinnamoyl methane derivatives as curcumin (min. 1.0%) — Compendial specification for the herbal substance cited by EMA. [P1]
- Identity test for xanthorrhizol and absence of bisdemethoxycurcumin — These features distinguish Javanese turmeric from common turmeric (Curcuma longa). [P1]
Supply and conservation
- IUCN Red List: Data Deficient (DD), via GBIF species API, retrieved 2026-10-29 [P6]
Absorption in people
- EMA: there are no pharmacokinetic data for xanthorrhizol; low systemic bioavailability of curcumin after oral dosing has been demonstrated. [P1]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Stated in the EU herbal monograph (traditional use, adults; HMPC, adopted 28 January 2014): herbal tea, 1 g comminuted rhizome in 100 ml boiling water 3 times daily; dry extract (DER 20-50:1, ethanol 96%) 8-13 mg 3 times daily; dry extract (DER 9-12:1, acetone) 50-100 mg twice daily. [P4]
Pregnancy and breastfeeding
- EU monograph: safety during pregnancy and lactation has not been established; use is not recommended. No fertility data. [P4]
Sources for this profile
- EMA HMPC. Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma, EMA/HMPC/604598/2012 (final, 28 January 2014), 2014-01-28. ema.europa.eu
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- EMA HMPC. Community herbal monograph on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma, EMA/HMPC/604600/2012 (final, adopted 28 January 2014), 2014-01-28. ema.europa.eu
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, checked 2026-10-29), 2026-10-29. ecfr.gov
- GBIF species API: IUCN Red List category for Curcuma zanthorrhiza, 2026-10-29. api.gbif.org
Sources
- EMA HMPC. Assessment report on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma, EMA/HMPC/604598/2012 (final, 28 January 2014), 2014-01-28. ema.europa.eu
- European Medicines Agency. Curcumae xanthorrhizae rhizoma (Javanese turmeric) - herbal medicinal product: overview and summary for the public (EMA/654803/2016, published 02/12/2016), 2016-12-02. ema.europa.eu
- Khalid GS, et al. Antibacterial and antimicrobial effects of xanthorrhizol in the prevention of dental caries: a systematic review. Drug Des Devel Ther 2021;15:1149-1156 (PMID 33731986), 2021. pubmed.ncbi.nlm.nih.gov
- EMA HMPC. Community herbal monograph on Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich), rhizoma, EMA/HMPC/604600/2012 (final, adopted 28 January 2014), 2014-01-28. ema.europa.eu
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Curcuma zanthorrhiza Roxb. (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- Singgih Wahono C, et al. Effect of Curcuma xanthorrhiza Supplementation on Systemic Lupus Erythematosus Patients with Hypovitamin D Which Were Given Vitamin D(3) towards Disease Activity (SLEDAI), IL-6, and TGF-β1 Serum. Int J Rheumatol 2017;2017:7687053 (PMID 29445400), 2017-12-28. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.